Drug intelligence / Profile preview

CCNU + carbamazepine

Development stage
Unknown
Lead developer
Bristol Myers Squibb
Modality
Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral
01

Overview

CCNU + carbamazepine is a combination of two pharmaceutical agents used in clinical settings where both drugs are indicated. - **Lomustine (CCNU)** is an oral alkylating agent of the nitrosourea class primarily used as part of combination chemotherapy for primary and metastatic brain tumors and as secondary therapy for refractory or relapsed Hodgkin's disease. It acts by interfering with DNA and RNA function, leading to cell death in rapidly dividing cancer cells[2][5]. - **Carbamazepine** is an anticonvulsant and analgesic drug indicated for epilepsy (including partial seizures and generalized tonic-clonic seizures), trigeminal neuralgia pain, and bipolar disorder. It works mainly by inhibiting voltage-gated sodium channels in neuronal membranes, stabilizing hyperexcited nerve membranes[1]. When combined, these drugs may be co-administered in patients with brain tumors who also require seizure control; however, caution is warranted due to potential pharmacokinetic interactions—carbamazepine can induce hepatic enzymes that may alter the metabolism or toxicity profile of chemotherapeutic agents like lomustine[5][6].

Brand names
CeeNUTegretol
Other names
lomustine + carbamazepineCCNU + carbamazepine
02

Targets

SCN3A (Sodium channel protein type 3 subunit alpha)DNA

Beyond the preview

Go deeper on CCNU + carbamazepine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCNU + carbamazepine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call